SCHEMBL2008304

SCHEMBL2008304

CC(C)COC(=O)COc1ccc(C(=O)CN2Cc3cc(C#N)ccc3C2=O)cc1OCC(=O)OCC(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.38
MAPT P10636 1/20 0.38
PDE4B Q07343 2/20 0.38
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
ITGB3 P05106 2/20 0.34
ITGA2B P08514 2/20 0.34
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008790 0.91 ITGB3 (0.39) MAPTL3MBTL1PRMT5WDR77ITGB3
SCHEMBL2011031 0.91 GABRA1 (0.40) USP2MAPTPDE4BPRMT5WDR77
SCHEMBL2009796 0.85 ITGB3 (0.45) PDE4BTSHRTDP1L3MBTL1ITGB3
SCHEMBL2009016 0.85 PDE4B (0.40) MAPTPDE4BTSHRTDP1L3MBTL1
SCHEMBL2009644 0.84 PDE4B (0.37) PDE4BTSHRTDP1L3MBTL1ITGB3
SCHEMBL2009466 0.83 GABRA1 (0.39) USP2MAPTTSHRTDP1L3MBTL1
SCHEMBL2009871 0.81 GABRA1 (0.37) USP2MAPTTSHRPRMT5WDR77
SCHEMBL3601635 0.81 GABRA1 (0.37) USP2MAPTPRMT5WDR77ITGB3
SCHEMBL2012689 0.81 ALK (0.45) MAPTL3MBTL1ITGB3ITGA2BGABRA1
SCHEMBL2008978 0.80 GABRA1 (0.37) USP2MAPTPDE4BPRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 USP2 4581/4885MAPT 4727/4885PDE4B 4262/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 USP2 4581/4885MAPT 4727/4885PDE4B 4262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.